Combined vitreoretinal-cataract system (VCS) is cleared for use in Canada New, proprietary technology is designed to deliver significant surgical and workflow efficiencies First innovation to be introduced from Alcon’s cutting-edge Unity portfolio of surgical equipment TORONTO / Jul 08, 2025 / Business Wire / Alcon, the global leader in eye care dedicated to helping people see brilliantly, today announced that UNITY® Vitreoretinal Cataract System (VCS) has received... Read more
Abbott continues to transform diabetes care with its leading Libre systems and the new FreeStyle Libre 3 Plus* sensor MISSISSAUGA, ON, July 8, 2025 /CNW/ -- Abbott (NYSE: ABT) today announced that its latest generation of sensor-based glucose monitoring technology, the FreeStyle Libre 3 Plus* sensor, is now available to Canadians living with diabetes. This innovative product features the world's smallest1,2 glucose sensor. Glucose monitoring is key... Read more
LumiThera’s photobiomodulation (PBM) device is the first and only technology that has demonstrated meaningful visual improvement with two years of treatments* in early and intermediate dry AMD patients1,2 Nearly 200 million people globally live with dry AMD, a progressive disease with no cure, and a leading cause of blindness in developed nations3,4 Alcon aims to expand PBM office-based treatment in approved markets, underscoring its commitment to people living with... Read more
The FARAPULSE PFA System now approved for pulmonary vein and posterior wall ablation in patients with persistent atrial fibrillation MARLBOROUGH, Mass., July 7, 2025 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) has received U.S. Food and Drug Administration (FDA) approval to expand the instructions for use (IFU) labeling for the FARAPULSE™ Pulsed Field Ablation (PFA) System. The updated labeling now includes approval for the system in the treatment of... Read more
Fifth-generation da Vinci surgical system approved for use in Europe across multiple procedures SUNNYVALE, Calif., July 02, 2025 (GLOBE NEWSWIRE) -- Intuitive (NASDAQ:ISRG), a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery, announced today that the da Vinci 5 Surgical System has received CE mark approval for adult and pediatric use in Europe for minimally invasive endoscopic procedures across abdominopelvic... Read more
Streamlining total ankle replacement with data-driven implants and surgical flexibility PORTAGE, Mich. / Jun 25, 2025 / Business Wire / Stryker (NYSE:SYK), a global leader in medical technologies, announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for the Incompass® Total Ankle System, an implant intended for patients with ankle joints damaged by severe rheumatoid, post-traumatic, or degenerative arthritis. This new platform integrates... Read more
Combines highly complementary proteomics expertise with Illumina's industry-leading product innovation and global market reach Positions Illumina to achieve growth in a large, expanding market Illumina and SomaLogic have partnered in proteomics co-development since late 2021 SAN DIEGO, June 23, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) announced today it has entered into a definitive agreement with Standard BioTools (NASDAQ: LAB) under which Illumina will... Read more
Clareon PanOptix Pro has half the light scatter of Clareon PanOptix1-3,*,** PanOptix Pro provides an unprecedented 94% light utilization, compared to a theoretical maximum utilization of 96% for diffractive optics1-4,*,**,† Clareon PanOptix Pro provides more uninterrupted light distribution across the full visual range, and is designed for better image contrast1,††,‡ TORONTO / Jun 20, 2025 / Business Wire / Alcon (SIX/NYSE: ALC), the global leader in eye care... Read more
New offering delivers convenient, comprehensive lab testing solutions for functional medicine, integrative medicine and primary care providers BURLINGTON, N.C., June 18, 2025 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today the launch of Labcorp Whole Health Solutions to support the growing needs of functional medicine, integrative medicine and primary care providers in delivering holistic... Read more
The test, run on Abbott's portable i-STAT® Alinity® instrument, uses whole blood to help evaluate patients with a suspected mild traumatic brain injury (mTBI), otherwise known as concussion The test produces lab-quality results in 15 minutes Clinicians can get a result at the patient's bedside, making the test accessible at urgent care clinics and healthcare settings outside of the hospital emergency room The test can be used to help evaluate patients up to 24 hours... Read more
RESEARCH TRIANGLE PARK, N.C. / Jun 11, 2025 / Business Wire / IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, unveils AI agents at GTC Paris. IQVIA’s new custom-built AI agents using NVIDIA technology are designed to enhance workflows and accelerate insights for life sciences. These live applications of agentic architectures illustrate how IQVIA AI... Read more
Dexcom G7 sensor integration offers more customers the ability to manage diabetes from their iPhone, for additional convenience ACTON, Mass. / Jun 10, 2025 / Business Wire / Insulet Corporation (NASDAQ: PODD), the global leader in tubeless insulin pump technology, is excited to announce that the Omnipod® 5 App for iPhone is now compatible with the Dexcom G7 Continuous Glucose Monitoring (CGM) System. With this latest integration, the Omnipod 5 Automated Insulin Delivery... Read more
Kendall DL™ Multi System simplifies patient monitoring, drives efficiencies for providers DUBLIN, Ohio, June 4, 2025 /PRNewswire/ -- Cardinal Health (NYSE: CAH) announced today the U.S. launch of its multi-parameter, single-patient use monitoring cable and lead wire system that enables the continuous monitoring of cardiac activity, blood oxygen level and temperature with one point of connection. The new Kendall DL™ Multi System is designed to travel with... Read more
MARLBOROUGH, Mass. / Jun 02, 2025 / Business Wire / SCIEX, a global leader in life science analytical technologies and operating company of Danaher Corporation (NYSE: DHR), announces three software ecosystem enhancements at ASMS. These developments will present new ways to acquire data, new standards for performance, and new practices to extract elevated insights, all supporting the theme that “all science is data science now.” The new SCIEX OS software version 4.0 is... Read more
MARLBOROUGH, Mass. / Jun 02, 2025 / Business Wire / SCIEX, a global leader in life science analytical technologies and operating company of Danaher Corporation (NYSE: DHR), and Evosep Biosystems, a global leader in proteomics solutions, enter a reseller agreement to co-sell SCIEX mass spectrometry systems with the newly announced Evosep Eno, for standardized high-throughput proteomics. The reseller agreement empowers researchers to implement standardized proteomics workflows,... Read more
New test offerings target solid tumors and hematologic malignancies Enhanced biopharma services support accelerated clinical trials and companion diagnostic development BURLINGTON, N.C., May 30, 2025 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today the expansion of its precision oncology portfolio. The additions include new test offerings for solid tumor and hematologic malignancies... Read more
Danaher has entered a partnership with AstraZeneca to scale precision medicine, including developing the next generation of AI-powered diagnostics This partnership aims to create a framework for rapid diagnostics research, development and commercialization Danaher, through its Centers for Enabling Precision Medicine, will provide support in all aspects of the development cycle across diagnostic modalities WASHINGTON, May 29, 2025 /PRNewswire/ -- Danaher Corporation... Read more
New AI algorithm accurately deciphers pathogenic regulatory genetic variants in the noncoding regions of the human genome at scale for the first time SAN DIEGO, May 29, 2025 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN) today unveiled PromoterAI, a new AI algorithm that accurately deciphers pathogenic regulatory genetic variants in the noncoding regions of the human genome. A study published today in Science illustrates how this deep learning technology discovered regulatory... Read more
In pivotal Phase 3 trials, TRYPTYR demonstrated rapid natural tear production as early as Day 11-2 TRYPTYR is a first-in-class TRPM8 receptor agonist that rapidly stimulates natural tear production in patients with Dry Eye Disease (DED)3 Approximately 38 million individuals in the U.S. are living with DED, yet less than 10% of diagnosed patients are being treated with a prescription product4 GENEVA / May 28, 2025 / Business Wire / Alcon (SIX/NYSE: ALC), the global... Read more
Agilent delivers strong quarter, enabled by Ignite Transformation Highlights Revenue of $1.67 billion for the second quarter ended April 30, 2025, representing growth of 6.0% reported and up 5.3% on a core(1) basis compared with the second quarter of 2024. GAAP net income of $215 million; earnings per share (EPS) of $0.75, down 29% from the second quarter of 2024. Non-GAAP(2) net income of $373 million; EPS of $1.31, up 7% from the second quarter of 2024. Outlook... Read more
FRANKLIN LAKES, N.J., May 28, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced plans to initiate a patient data registry for the Rotarex™ Atherectomy System to measure real-world outcomes for patients with peripheral artery disease (PAD). Known as "XTRACT," this prospective, multi-center, single-arm, post-market registry study will assess the clinical performance of the Rotarex™... Read more
The Tendyne system replaces mitral valves that are not functioning properly due to a buildup of calcium in the base of the valves, known as severe mitral annular calcification (MAC) Tendyne offers a new treatment option for patients who are not candidates for open-heart surgery or mitral repair This approval expands Abbott's portfolio of minimally invasive structural heart therapies in the U.S. ABBOTT PARK, Ill., May 27, 2025 /PRNewswire/ -- Abbott (NYSE: ABT)... Read more
Setting new standards for intelligent mass detection, sensitivity, and sustainability SANTA CLARA, Calif. / May 27, 2025 / Business Wire / Agilent Technologies Inc. (NYSE: A) today announced the launch of its latest innovation in liquid chromatography (LC)-mass detection: the Agilent InfinityLab Pro iQ Series. This groundbreaking series includes the InfinityLab Pro iQ and the InfinityLab Pro iQ Plus, each tailored with distinct features and capabilities to meet the diverse... Read more
Building momentum in key franchises including Pulsed Field Ablation, TAVR, Cardiac Rhythm Management, Diabetes, Spine, and Neuromodulation GALWAY, Ireland, May 21, 2025 /CNW/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced financial results for its fourth quarter (Q4) and fiscal year 2025 (FY25), which ended April 25, 2025. Q4 Key Highlights Q4 revenue of $8.9 billion increased 3.9% as reported and 5.4% organic Q4 GAAP diluted... Read more
FRANKLIN LAKES, N.J., May 21, 2025 /PRNewswire/ -- First-of-their-kind studies published in The Lancet Oncology1 and Cancer Medicine2 provide new data showing that cancer patients in both hospital and outpatient settings are at a substantially higher risk of developing antimicrobial resistant (AMR) infections compared to all other non-cancer patients. Key Takeaways: The studies, led by the Cancer and AMR Consortium, which includes BD (Becton, Dickinson and... Read more
Enables intense focus on highest margin growth drivers where Medtronic has leading core competencies Leading, scaled, direct-to-consumer Diabetes business poised to become standalone company; only company with a complete ecosystem to address intensive insulin management GALWAY, Ireland, May 21, 2025 /CNW/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced its intent to separate its Diabetes business into a new standalone company... Read more
Stryker's first basivertebral nerve ablation system targets the basivertebral nerve to provide relief from chronic* vertebrogenic low back pain. PORTAGE, Mich., May 19, 2025 /PRNewswire/ -- Stryker (NYSE:SYK), a global leader in medical technologies, announced that its OptaBlate basivertebral nerve ablation system (OptaBlate BVN) received 510(k) clearance from the U.S. Food and Drug Administration. OptaBlate BVNA is used in a targeted minimally invasive procedure providing... Read more
N of 1 therapy uniquely developed, on demand, for infant with life-threatening rare metabolic disorder in six months Results published in The New England Journal of Medicine and showcased at American Society of Gene & Cell Therapy Annual Meeting FARGO, N.D. & CORALVILLE, Iowa / May 15, 2025 / Business Wire / Aldevron, a global leader in the production of DNA, RNA and protein, together with Integrated DNA Technologies (IDT), a global leader in genomics solutions,... Read more
New data reveal a 78% reduction in cardiovascular disease-related hospitalizations for people living with Type 1 diabetes with prior severe low blood sugar episodes.1 This significant decrease is linked to the use of Libre biowearable technology compared to traditional blood glucose monitors.1 Results also show a reduction in hospitalization for cardiovascular complications in adults with Type 2 diabetes on insulin using Libre technology.2 ABBOTT PARK, Ill., May... Read more
Full year fiscal 2025 revenue from continuing operations increased 6%; constant currency organic revenue growth was 6% Full year fiscal 2025 as reported diluted EPS from continuing operations increased to $6.16; adjusted EPS per diluted share increased to $9.22 Fiscal 2026 outlook provided DUBLIN, IRELAND, May 14, 2025 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) today announced financial results for its fiscal 2025 fourth quarter... Read more
First-quarter 2025 sales of $2.5 billion, in line on a reported basis, or up 3% constant currency1 (cc), versus first-quarter 2024 First-quarter 2025 diluted EPS of $0.70; core diluted EPS2 of $0.73 Generated $384 million cash from operations and $278 million free cash flow3 Dividend of CHF 0.28 per share approved by shareholders at the Annual General Meeting on May 6, 2025 Launched rich pipeline of innovative products, including Voyager, Precision7 and Systane Pro... Read more
Building on reputation for unparalleled performance, latest software delivers even greater accuracy, with 30% improvement in structural variant calling New features include easy-to-use oncology apps, enhanced multiomics pipelines, and AWS F2 support enabling faster turnaround times SAN DIEGO, May 13, 2025 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN) today announced the launch of DRAGEN™ version 4.4 software (v4.4), the industry's most comprehensive secondary analysis... Read more
New BD FACSDiscover™ A8 Cell Analyzer Brings Leading-Edge Capabilities to Wider Range of Scientists across Academia and Biopharma FRANKLIN LAKES, N.J., May 13, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced the global commercial launch of the world's first cell analyzer featuring breakthrough spectral and real-time cell imaging technologies, enabling more researchers across a wider range... Read more
Core Illumina revenue of $1.04 billion for Q1 2025, down 1% from Q1 2024 (flat on a constant currency basis) GAAP operating margin of 15.8% and non-GAAP operating margin of 20.4% for Q1 2025 GAAP diluted EPS of $0.82 and non-GAAP diluted EPS of $0.97 for Q1 2025 Cash provided by operations of $240 million and free cash flow of $208 million for Q1 2025 For fiscal year 2025, we expect: Core Illumina revenue to decline between (1%) and (3%) on a constant currency... Read more
Revenue of $3,829 million GAAP Net Income of $249 million, Adjusted EBITDA of $883 million GAAP Diluted Earnings per Share of $1.40, Adjusted Diluted Earnings per Share of $2.70 R&D Solutions quarterly bookings of $2.1 billion, resulting in trailing-twelve-month bookings of $9.7 billion and a trailing-twelve-month book-to-bill ratio of 1.14x R&D Solutions contracted backlog of $31.5 billion, up 4.8 percent year-over-year TAS Revenue of $1,546 million, up 6.4... Read more
First quarter net sales of $1.909 billion increased 1.1% and 2.3% on a constant currency1 basis First quarter diluted earnings per share were $0.91; adjusted1 diluted earnings per share were $1.81 Company updates full-year 2025 reported revenue guidance to include the Paragon 28 acquisition and currency expectations, and full-year 2025 adjusted1 earnings per share guidance to include Paragon 28, currency and the impact from current tariff proposals WARSAW, Ind.,... Read more
SAN DIEGO / May 01, 2025 / Business Wire / DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter ended March 31, 2025. First Quarter 2025 Financial Highlights: Revenue grew 12% year-over-year to $1.036 billion on a reported basis and 14% year-over-year on an organic1 basis. U.S. revenue grew 15% and international revenue grew 7% on a reported basis and 12% on an organic1 basis, all on a year-over-year basis. GAAP operating income... Read more
Portage, Michigan, May 01, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) reported operating results for the first quarter of 2025: First Quarter Results Reported net sales increased 11.9% to $5.9 billion Organic net sales increased 10.1% Reported operating income margin of 14.3% Adjusted operating income margin(1) increased 100 bps to 22.9% Reported EPS decreased 17.6% to $1.69 Adjusted EPS(1) increased 13.6% to $2.84 First Quarter Net Sales Growth... Read more
First real-world dataset with integrated clinical and multiomic insights from 25,000 patients treated with GLP-1 therapies Dataset will advance development of GLP-1 therapies in new indications and accelerate discovery of novel drug targets in patients who are unresponsive to therapies SAN DIEGO, May 1, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), and Ovation.io, Inc., an organization dedicated to building best-in-class multiomics datasets, today... Read more
SUNNYVALE, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- Intuitive (NASDAQ: ISRG), a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery, announced today that the U.S. Food and Drug Administration (FDA) cleared the da Vinci Single Port (SP) surgical system for transanal local excision/resection, a form of minimally invasive surgery performed through a natural orifice to avoid abdominal surgical incisions for select procedures. This... Read more
SAN DIEGO, May 01, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing, and care delivered in the home, today announced it has acquired VirtuOx, a leading independent diagnostic testing facility (IDTF) for sleep, respiratory, and cardiac conditions. The acquisition reflects Resmed’s commitment to improving the way care is delivered—by making it more accessible, more coordinated, and more patient friendly.... Read more
SANTA CLARA, Calif. / May 01, 2025 / Business Wire / Agilent Technologies Inc. (NYSE: A) today announced release of the new Seahorse XF Flex Analyzer, a high-performance, 24-well system designed to expand real-time metabolic analysis into optimized 3D tissue and organoid workflows, along with dedicated consumables and kit. Metabolism is vital for cellular functions, driving energy production and essential processes such as biosynthesis, adaptation, redox balance, mitochondrial... Read more
Transforming Care for Severe AS Patients IRVINE, Calif. / May 01, 2025 / Business Wire / Edwards Lifesciences (NYSE: EW) announced today that the U.S. Food and Drug Administration (FDA) has approved its transcatheter aortic valve replacement (TAVR) therapy, the SAPIEN 3 platform, for severe aortic stenosis (AS) patients without symptoms, marking the first FDA approval for TAVR in asymptomatic patients. Approval of the SAPIEN 3 platform (SAPIEN 3, SAPIEN 3 Ultra and... Read more
First-quarter sales from continuing operations of $2.63 billion increased 5% on both a reported and operational basis, exceeding the company’s previously issued guidance1,2 First-quarter U.S. GAAP3 diluted earnings per share (EPS) from continuing operations of $0.13; adjusted diluted EPS from continuing operations of $0.55, exceeding the company’s previously issued guidance Baxter increases bottom end of previous range for full-year 2025 adjusted diluted EPS guidance... Read more
Revenue was flat at $54.9 billion; revenue increased 19% excluding the impact of the previously communicated customer contract expiration GAAP1 operating earnings were $730 million; GAAP diluted EPS was $2.10 Non-GAAP operating earnings increased 21% to $807 million, driven by segment profit growth across all of the company's operating segments; non-GAAP diluted EPS increased 13% to $2.35 Fiscal year 2025 non-GAAP EPS guidance2 raised and narrowed to $8.05 to $8.15,... Read more
Revenue of $5.3 billion increased 4.5% as reported, 6.0% currency-neutral and 0.9% organic GAAP and adjusted diluted EPS of $1.07 and $3.35, respectively Company updates full-year fiscal 2025 guidance and provides estimated tariff impact FRANKLIN LAKES, N.J., May 1, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced results for its fiscal 2025 second quarter, which ended March 31,... Read more
Highlights Net business wins in the quarter of $2,022 million; a net book to bill in the quarter of 1.01. Closing backlog of $24.7 billion, an increase of 0.3% on quarter four 2024 and 6.0% on quarter one 2024. Quarter one revenue was $2,001.3 million and quarter one adjusted EBITDA was $390.7 million or 19.5% of revenue. GAAP net income for the quarter was $154.2 million or $1.90 per diluted share. Quarter one adjusted net income was $258.3 million or $3.19 per diluted... Read more
Collaboration brings together FreeStyle Libre® Systems, the world's leading continuous glucose monitoring technology (CGM)1 with Epic, a healthcare software company, to streamline access to CGM data for healthcare organizations Integration empowers U.S. clinicians to enhance patient care by incorporating Libre's data directly into their workflows ABBOTT PARK, Ill., April 29, 2025 /PRNewswire/ -- Abbott (NYSE: ABT), the global leader in continuous glucose monitoring... Read more
Updates Full-Year Guidance Results from Operations for first quarter 2025 versus first quarter last year: Revenue: $3.35 billion versus $3.18 billion Diluted EPS: $2.52 versus $2.69 Adjusted EPS: $3.84 versus $3.68 Reaffirmed Revenue and Free Cash Flow guidance, raised midpoint of adjusted EPS: Revenue guidance of 6.7% to 8.0% Adjusted EPS range of $15.70 to $16.40; midpoint raised $0.05 Free Cash Flow of $1.10 billion to $1.25 billion Providing broader... Read more
One-year clinical trial data for the next-generation, investigational, Sphere-360™ single-shot PFA catheter show impressive safety, performance, and efficiency results for paroxysmal Afib Dual-energy (RF/PF), focal Sphere-9™ catheter demonstrates efficacy for linear ablation in persistent AFib Medtronic continues legacy of leadership in innovation, showcasing arrhythmia management portfolio at Heart Rhythm Society annual meeting GALWAY, Ireland and SAN DIEGO,... Read more
